DK1359906T3 - Farmaceutiske sammensætninger indeholdende fluorerede eller perfluorerede carboxylsyrer - Google Patents

Farmaceutiske sammensætninger indeholdende fluorerede eller perfluorerede carboxylsyrer

Info

Publication number
DK1359906T3
DK1359906T3 DK02712094T DK02712094T DK1359906T3 DK 1359906 T3 DK1359906 T3 DK 1359906T3 DK 02712094 T DK02712094 T DK 02712094T DK 02712094 T DK02712094 T DK 02712094T DK 1359906 T3 DK1359906 T3 DK 1359906T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical compositions
carboxylic acids
compositions containing
containing fluorinated
perfluorinated carboxylic
Prior art date
Application number
DK02712094T
Other languages
Danish (da)
English (en)
Inventor
Clifford Roy Elcombe
Charles Roland Wolf
Original Assignee
Cxr Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cxr Biosciences Ltd filed Critical Cxr Biosciences Ltd
Application granted granted Critical
Publication of DK1359906T3 publication Critical patent/DK1359906T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
DK02712094T 2001-02-16 2002-02-18 Farmaceutiske sammensætninger indeholdende fluorerede eller perfluorerede carboxylsyrer DK1359906T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0103809.0A GB0103809D0 (en) 2001-02-16 2001-02-16 Methods
PCT/GB2002/000726 WO2002066028A2 (en) 2001-02-16 2002-02-18 Pharmaceutical compositions containing fluorinated or perfluorinated carboxylic acids

Publications (1)

Publication Number Publication Date
DK1359906T3 true DK1359906T3 (da) 2008-09-15

Family

ID=9908862

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02712094T DK1359906T3 (da) 2001-02-16 2002-02-18 Farmaceutiske sammensætninger indeholdende fluorerede eller perfluorerede carboxylsyrer

Country Status (13)

Country Link
US (2) US8487003B2 (pt)
EP (3) EP1359906B1 (pt)
JP (2) JP4652665B2 (pt)
AT (1) ATE395054T1 (pt)
AU (3) AU2002232001B2 (pt)
CA (2) CA2438085C (pt)
CY (1) CY1108262T1 (pt)
DE (1) DE60226575D1 (pt)
DK (1) DK1359906T3 (pt)
ES (1) ES2309153T3 (pt)
GB (2) GB0103809D0 (pt)
PT (1) PT1359906E (pt)
WO (1) WO2002066028A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220045D0 (en) * 2002-08-29 2002-10-09 Cxr Biosciences Ltd Sc 211745 Methods
AU2009334794B2 (en) * 2009-01-02 2014-12-04 Bgp Products Ireland Limited Novel use of fibrates
EP2459182B1 (en) 2009-07-30 2017-09-06 University of Zürich Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event
GB201002861D0 (en) * 2010-02-19 2010-04-07 Cxr Biosciences Ltd Compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2567011A (en) 1949-01-10 1951-09-04 Minnesota Mining & Mfg Fluorocarbon acids and derivatives
US4624851A (en) 1983-04-22 1986-11-25 Elena Avram Treatment of symptoms of neoplastic diseases
DE4040619A1 (de) * 1990-12-19 1992-06-25 Boehringer Mannheim Gmbh Neue aliphatische amide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5621144A (en) 1991-11-29 1997-04-15 Isis Innovation Limited Fluorinated compounds as oxygen transport agents
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US6013795A (en) 1996-11-04 2000-01-11 3M Innovative Properties Company Alpha-branched fluoroalkylcarbonyl fluorides and their derivatives
US6015838A (en) 1996-11-04 2000-01-18 3M Innovative Properties Company Aqueous film-forming foam compositions
AU750313B2 (en) 1998-07-27 2002-07-18 St. Jude Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
GB9917405D0 (en) 1999-07-23 1999-09-22 Univ Dundee Methods of treatment and drug screening methods
GB0220045D0 (en) 2002-08-29 2002-10-09 Cxr Biosciences Ltd Sc 211745 Methods
US6875060B2 (en) 2002-10-21 2005-04-05 Adc Telecommunications, Inc. High density patching system

Also Published As

Publication number Publication date
CA2438085C (en) 2011-05-03
CY1108262T1 (el) 2014-02-12
US20050175639A1 (en) 2005-08-11
US8487003B2 (en) 2013-07-16
PT1359906E (pt) 2008-08-26
EP1745779A2 (en) 2007-01-24
JP2004531482A (ja) 2004-10-14
ES2309153T3 (es) 2008-12-16
GB2383535A (en) 2003-07-02
EP1359906A2 (en) 2003-11-12
ATE395054T1 (de) 2008-05-15
CA2438085A1 (en) 2002-08-29
JP2009132726A (ja) 2009-06-18
DE60226575D1 (de) 2008-06-26
AU2002232001B2 (en) 2006-06-29
GB0203716D0 (en) 2002-04-03
AU2006222766B2 (en) 2009-08-06
EP1745779A3 (en) 2011-05-04
AU2009233689A1 (en) 2009-11-26
GB0103809D0 (en) 2001-04-04
GB2383535B (en) 2005-09-21
WO2002066028A2 (en) 2002-08-29
WO2002066028A3 (en) 2002-11-14
JP4652665B2 (ja) 2011-03-16
AU2006222766A1 (en) 2006-11-02
EP2260842A2 (en) 2010-12-15
CA2737095A1 (en) 2002-08-29
US20120029079A1 (en) 2012-02-02
EP1359906B1 (en) 2008-05-14

Similar Documents

Publication Publication Date Title
FR2799759B1 (fr) Composition, notamment cosmetique, comprenant une sapogenine
RS50133B (sr) Upotreba preparata koji sadrži epa
DE60207234D1 (de) Verfahren zur herstellung einer gereinigten shilajit-zusammensetzung aus nativem shilajit
CY1108262T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν φθοριωμενα ή υπερφθοριωμενα καρβοξυλικα οξεα
NO991635L (no) Farmas°ytisk preparat omfattende eikospentaensyre og/eller stearidonsyre
BR0100765A (pt) Processo para o processamento de composições de borracha contendo ácidos graxos de soja, ácidos graxos de girassol e suas misturas
DE60143168D1 (de) Liposomzusammensetzungen, Paclitaxel enthaltend, zur Behandlung von Krebs und deren Zubereitung
ATE388690T1 (de) Stabilisierung aktiver wirkstoffe durch formulierung als nanopartikuläre zusammensetzungen
FR2792191B1 (fr) Composition cosmetique comprenant l'association d'un ester particulier et d'un compose silicone
ES2109735T3 (es) Composiciones adhesivas activables por humedad.
FI956341A (fi) Metyylifosfonihappoesteri, menetelmä sen valmistamiseksi ja sen käyttö
ATE372107T1 (de) Befeuchtungsmittel und dieses enthaltende kosmetika und topische präparate
BR0215027A (pt) Derivados de 6-aminomorfinano, processo de preparação para o mesmo e sua aplicação
AU7448694A (en) Inclusion complex
FR2833834B1 (fr) Composition pour la teinture d'oxydation des fibres keratiniques comprenant un acide ether carboxylique oxyalkylene, un tensioactif mono-ou poly-glycerole et un alcool gras insature
DE69607247D1 (de) Hydraulische Flüssigkeitzusammensetzung
MY128392A (en) 6ALPHA, 9ALPHA-DIFLUORO-17ALPHA-(2-FURANYLCARBOXYL)OXY]-11ß-HYDROXY-16ALPHA-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT
BR0208275A (pt) Composições farmacêuticas para tratamento de arteriosclerose
BR0116835A (pt) Composição e processo
DE602007005730D1 (de) Stärke und PEG Diester Fettsäure enthaltende kosmetische Zusammensetzungen und ihre Verwendungen
SE9903915L (sv) Kolesterolsänkande och blodfettsänkande komposition
ATE360027T1 (de) 11beta-langkettig-substituierte estratriene, verfahren zur herstellung, pharmazeutische präparate, die diese 11beta-langkettig- substituierten estratriene enthalten, sowie deren verwendung zur herstellung von arzneimitteln
ES2097296T3 (es) Composicion acida desinfectante con caracteristicas detergentes y desincrustantes y procedimiento para su fabricacion.
ATE297884T1 (de) Verfahren zur herstellung von 2-(4-(2,2,- dihalocyclopropyl)phenoxy)-alkansäuren und ihre estern
DE60022229D1 (de) Benzoesäureester und flüssigkristallmedium